4SC

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, 4SC had revenue of €304K and net profit of -€8.24M

(EUR)	2023	YoY
Revenue	304K	30.28%
Gross profit	209K	25.62%
Net profit	-8.24M	42.64%
EBITDA	-7.9M	39.54%

Fundamentals

Metric	Value
Market capitalization	€150.7M
Number of shares	50.57M
52-week high/low	€3.46 - €1.17
Dividends	No
Beta	0.00
P/E ratio	-3.68
PEG ratio	-0.08
P/B ratio	5.97
P/S ratio	495.72

Company profile

4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.